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ABSTRACT
Invasive aspergillosis is difficult to diagnose in patients undergoing hematopoietic stem cell transplantation
(HSCT). In 2003, a serum enzyme-linked immunosorbent assay (ELISA) test for the detection of galactoman-
nan (a glycoprotein found on the Aspergillus cell wall) became available in the United States. In 2004, patients
undergoing HSCT were screened biweekly with the galactomannan ELISA at our institution. We performed
a retrospective chart review of 121 SCT patients who underwent galactomannan testing. Thirteen of the
patients (10.7%) had at least 1 positive galactomannan ELISA, and 4 had multiple positive tests. When
calculated in reference to a proved or probable diagnosis of aspergillosis, the galactomannan ELISA had a
sensitivity of 0.50 and a specificity of 0.94. The positive predictive value was 0.46, and the negative predictive
value was 0.94. Galactomannan ELISA had fewer false-positive and false-negative results in pediatric patients
than in adult patients. In 4 of the 12 cases of invasive aspergillosis, the galactomannan ELISA was positive
before other microbiologic evidence of aspergillosis was available. In these cases, a positive ELISA predated
culture and cytologic evidence of invasive aspergillosis by a mean of 5 days (range, 1-8 days). Our findings
indicate that a biweekly serum galactomannan ELISA is a highly specific diagnostic tool for detecting invasive
aspergillosis in patients undergoing HSCT. When used regularly, the ELISA may allow for earlier diagnosis of
invasive aspergillosis in some patients. The test is troubled by a low sensitivity and high frequency of
false-negative tests.
© 2007 American Society for Blood and Marrow Transplantation
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Invasive aspergillosis (IA) is a frequent and devas-
ating complication in patients who have undergone
ematopoietic stem cell transplantation (HSCT). The
iagnosis of IA remains a clinical challenge. Blood,
putum, and bronchoalveolar lavage cultures have low
peciﬁcity and sensitivity in detecting IA [1,2]. Radio-
raphic ﬁndings on computed tomography (CT) of
he chest are also frequently nonspeciﬁc [3,4].
In May 2003, the US Food and Drug Administra-
ion (FDA) approved a serum enzyme-linked immu-
osorbent assay (ELISA) test to detect the aspergillus
ell wall glycoprotein known as galactomannan (GM). t
40imilar antigen ELISAs for GM have been available in
urope since 1996 [5]. In 2001, the European Orga-
ization for the Research and Treatment of Cancer
EORTC)/National Institute of Allergy and Infec-
ious Diseases (NIAID) consortium included a posi-
ive serum GM ELISA as part of its deﬁnition of
linical opportunistic fungal infection in HSCT and
ancer patients [6]. Initial reports suggested speciﬁcity
anging from 81% to 94% and sensitivity ranging
rom 64% to 96% [7-9]. More recent observations
uggest a high rate of false-positive tests associated
ith beta-lactam antibiotics, particularly piperacillin-
azobactam [10-16].
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Aspergillus GM antigen assay in HSCT 441The aims of the present study were to better
eﬁne the positive and negative predictive value of
ualitative GM ELISA and to assess whether screen-
ng could lead to earlier diagnosis of IA in HSCT
atients.
ATIENTS AND METHODS
In 2004, all patients undergoing HSCT at the
niversity of Minnesota Medical Center were
creened with biweekly serum GM ELISAs while hos-
italized. Additional testing of GM on HSCT patients
utside the hospital was done as determined by clinical
roviders. Assays were performed on peripheral blood
erum in accordance with the manufacturer’s speciﬁ-
ations (Bio-Rad, Redmond, WA). The tests were
erformed on Tuesdays and Fridays in a clinical hos-
ital laboratory. Control samples were included in
ach assay batch to validate performance of the
LISA.
GM ELISA was reported as either positive or
egative, with a cutoff of 0.5 ng/mL. Patients were
etrospectively evaluated through June 30, 2005, to
llow a minimum of 6 months to a maximum of 18
onths follow-up. Prospectively collected data from
he University of Minnesota Blood and Marrow
ransplant Database, as well as all clinical data for
iagnosing fungal infections, including microbiology
ultures, cytology reports from bronchoalveolar la-
age procedures, biopsy ﬁndings, and CT scans, were
eviewed.
The probability of having an invasive fungal in-
ection at any time after HSCT was determined by
ORTC/NIAID criteria at the end of the follow-up
eriod. A patient was classiﬁed as proved IA if he or
he had a sterilely obtained specimen that was culture-
ositive for aspergillus; as probable IA if he or she had
icrobiologic evidence of aspergillus infection from
ther specimens, including sputum, bronchoalveolar
avage, and skin biopsy; as possible IA if he or she had
T evidence of pulmonary inﬁltrates in the setting of
igh clinical suspicion for fungal infection (neutrope-
ia, fever, or graft-versus-host disease [GVHD]); and
s no risk of IA if he or she failed to meet other
riteria. These probabilities were determined both
ith and without GM testing in each patient.
Review of GM-positive cases allowed for determi-
ation of true and false-positive GM assays. Sensitiv-
ty, speciﬁcity, and positive and negative predictive
alues of the GM ELISA were calculated based on the
linical diagnosis of probable or proven IA infection.
econdary analysis of adult and pediatric populations
as obtained with a cutoff of age 18 years at the time
f transplantation. In addition, the lead time from
ositive GM assay to proven or probable invasive
ungal infection was calculated.
PA total of 71 adult and 50 pediatric patients had at
east 2 GM ELISAs tested while undergoing HSCT in
004. These patients ranged in age from 0.4 to 68.1
ears (mean, 29.5 years) at the time of transplantation.
edian age for the tested patients was 25.3 years; 69
f the recipients were male (57%). The source of
ematopoietic stem cell grafts varied; 52 patients re-
eived 1 or more units of umbilical cord blood, 39
eceived sibling donor stem cells, 15 received unre-
ated donor stem cells, 11 received autologous stem
ells, and 1 received allogeneic natural killer cells.
hree patients underwent 2 consecutive (tandem)
ourses of myeloablative therapy (including total
ody irradiation) with autologous peripheral blood
SCT.
ESULTS
GM ELISA was tested 1523 times among the 121
atients, for an average of 12.6 tests per patient (range,
-53 tests). After a complete retrospective review of
ach patient’s clinical course, 28 of the 121 patients
ad no clinical, radiographic, or microbiological cri-
eria for IA. Of the remaining 93 patients, 2 had
roven IA by biopsy (1 patient with pulmonary as-
ergillosis by open lung biopsy and 1 patient with
erebral aspergillosis by brain biopsy). Ten patients
ad a probable diagnosis of IA, and 81 had a possible
iagnosis if IA.
Thirteen of the 121 (10.7%) patients had at least 1
ositive GM ELISA test. GM assays were positive in
of the 12 proven or probable IA patients. Seven
atients who had at least 1 positive GM assay were
etermined not to have proven or probable IA (false-
ositive GM assays): of these, 5 had possible IA, and 2
ad no IA. Four of the 12 patients with proven or
robable IA met the additional EORTC/NIAID cri-
eria for invasive fungal infection by having 2 positive
erum GMs.
The use of screening GM changed EORTC/
IAID classiﬁcation from possible IA to probable IA
n 2 patients. Clinical diagnosis of IA including and
xcluding GM testing is outlined in Table 1. As shown
n Figure 1, the GM ELISA had a speciﬁcity of 0.94,
ensitivity of 0.46, positive predictive value of 0.46,
nd negative predictive value of 0.94.
able 1. Clinical Certainty of IA Infection with and without the Use
f the GM ELISA
EORTC/NIAID
Classification of
Fungal Infection
Without Use of
GM ELISA, n (%)
With Use of
GM ELISA, n (%)
one 28 (23%) 28 (23%)
ossible 81 (67%) 79 (65%)
robable 10 (8%) 12 (10%)
roven 2 (2%) 2 (2%)
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P. C. Foy et al.442In a subset analysis of the 50 pediatric patients,
M was truly positive in 4, falsely positive in 1, and
alsely negative in 1. The pediatric group had a GM
ensitivity of 0.80, speciﬁcity of 0.978, positive predic-
ive value of 0.50, and negative predictive value of
.978.
In a subset analysis of the 71 adult patients, GM
as truly positive in 2, falsely positive in 6, and falsely
egative in 6. The adult group had a GM sensitivity of
.25, speciﬁcity of 0.907, positive predictive value of
.25, and negative predictive value of 0.907.
In 4 cases, the GM ELISA was positive in patients
ith neutropenic fevers before any radiographic and
icrobiologic evidence of IA was identiﬁed. In these
ases, the positive GM ELISA preceded the appear-
nce of other evidence by 1, 4, 7, and 8 days.
ISCUSSION
The diagnosis of IA remains a clinical challenge in
atients undergoing HSCT. Pancytopenia and coagu-
opathy associated with HSCT often prohibit more
ensitive and speciﬁc biopsy to diagnose aspergillosis.
he search for less-invasive testing for aspergillosis
as been problematic. Our analysis suggests that using
he serum GM ELISA for screening is a speciﬁc but
ot sensitive diagnostic test for detecting IA after
SCT. Our data suggest that the sensitivity of the
M ELISA is below the value of 80.7% reported
efore clearance by the FDA. Our sample size of 12
ases of proven/probable IA was about 1/3 that of the
DA (n  31). Although an increased patient popu-
ation would further clarify statistical limitations of the
M assay, some discrepancy between the sensitivity in
ur study and the FDA data can be attributed to
ariation in clinical practice.
The differences in GM ELISA test utility in adults
Figure 1. Diagnostic validity of the GM ELISA.nd children are difﬁcult to interpret. Our results muggest that GM ELISA may be more sensitive and
peciﬁc in pediatric populations than in adults. This
ontradicts previous analysis of European data sug-
esting that GM was associated with a higher rate of
alse-positive results [15] and lower speciﬁcity [10] in
ediatric populations. These differences may reﬂect
he lower cutoff value of 0.5 ng/mL used in the United
tates, or, alternatively, they may be related to differ-
nces in clinical practice, including the use of antibi-
tics known to give false-positive GM ELISA ﬁnd-
ngs.
Part of the challenge in assessing new tests for
iagnosing IA is that few patients undergo the gold
tandard biopsy. Our data may be limited by the fact
hat only 2 of 121 patients had a proved diagnosis of
A. However, our retrospective classiﬁcation of
roven or probable IA in 10.7% of patients is consis-
ent with the incidence reported in other HSCT pop-
lation studies [17]. EORTC/NIAID guidelines rec-
mmend initiating appropriate antifungal medications
or any probable diagnosis, and by convention, most
revious studies have combined probable and proven
iagnosis for assessing diagnostic tests [6].
To limit the false-positive rate, 2 positive serum
M assays have been required for a probable diagno-
is of invasive fungal infection according to EORTC/
IAID criteria established in 2001 [6]. Only 3.3% of
ur patients had multiple positive tests. By requiring
ultiple positive tests supporting the clinical ﬁndings
or a probable diagnosis, fewer patients are classiﬁed
s being false-positive. This increases the sensitivity of
he GM assay, but does so at a reduced sensitivity.
ecently published data now support the use of am-
hotericin B or other antimold therapy for a patient
ith 2 consecutive positive GM ELISAs [18]. These
uidelines argue that treatment for IA should be lim-
ted to those who meet highly speciﬁc diagnostic cri-
eria for invasive fungal infection, to minimize the
xposure of patients with false-positive diagnoses to
oxic drug therapy. Because piperacillin-tazobactam
herapy and other clinical circumstances might lead to
alse-positive results, these results may be reasonable,
ut as newer and less toxic treatments for IA have
ecome better deﬁned in the past 5 years, it may be
ore appropriate to initiate treatment with more sen-
itive but less speciﬁc diagnostic criteria. Requiring
nly 1 positive serum GM for a probable diagnosis of
nvasive fungal infection may be appropriate and more
linically useful and allow initiation of empirical but
linically guided use of antifungal therapy. It also may
llow earlier initiation of effective treatment, which is
specially important in very-high-risk populations like
SCT recipients.
The most promising aspect of our study likely lies
n the 4 cases in which serum GM ELISA preceded
ther tests in diagnosing IA. Whether biweekly or
ore frequent screening changes the clinical manage-
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Aspergillus GM antigen assay in HSCT 443ent of IA in HSCT patients is unclear. Analysis of
ntifungal treatments, timing of initial treatment, and
ortality need to be performed before a deﬁnitive
ssessment of screening GM can be made.
Biweekly serum GM for detecting invasive as-
ergillosis in SCT is a highly speciﬁc diagnostic tool.
hen used regularly, ELISA may allow for earlier
etection of IA in some patients. The test is troubled
y the low sensitivity and high frequency of false-
egative tests. Differences in the speciﬁcity and sen-
itivity in adult and pediatric populations warrant fur-
her investigation.
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